drugset / Trial / NCT01458301
Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with endometriosis.
Timeline
- Start
- 2011-10
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 3.75 mg | Subcutaneous |
| Subject | Relugolix | Small molecule | 10 mg | Oral |
| Subject | Relugolix | Small molecule | 20 mg | Oral |
| Subject | Relugolix | Small molecule | 40 mg | Oral |